tiprankstipranks
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
US Market
DMAC
Diamedica Therapeutics
RESEARCH TOOLSreports

Diamedica Therapeutics (DMAC) Income Statement

569 Followers

Diamedica Therapeutics Income Statement

Last quarter (Q4 2025), Diamedica Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Diamedica Therapeutics's net income was $-8.74M. See Diamedica Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 34.40M$ 26.68M$ 21.27M$ 14.00M$ 13.65M
Depreciation and Amortization
$ 43.00K$ 39.00K$ 30.00K$ 25.00K$ 24.00K
EBITDA
$ -34.35M$ -26.64M$ -21.24M$ -13.98M$ -13.62M
Operating Income
$ -34.40M$ -26.68M$ -21.27M$ -14.00M$ -13.65M
Other Income/Expenses
$ 1.66M$ 2.27M$ 1.93M$ 353.00K$ 82.00K
Pretax Income
$ -32.74M$ -24.41M$ -19.34M$ -13.65M$ -13.56M
Net Income
$ -32.77M$ -24.44M$ -19.38M$ -13.68M$ -13.59M
Per Share Metrics
Basic EPS
$ -0.70$ -0.60$ -0.60$ -0.52$ -0.65
Diluted EPS
$ -0.70$ -0.60$ -0.60$ -0.52$ -0.65
Weighted Average Shares Outstanding
 46.98M 40.40M 32.57M 26.44M 20.77M
Weighted Average Shares Outstanding (Diluted)
 46.98M 40.40M 32.57M 26.44M 20.77M
Currency in USD

Diamedica Therapeutics Earnings and Revenue History